Low Japan Funding Leads To Drug-Maker Dominance Of Medical Research
This article was originally published in PharmAsia News
Executive Summary
Japan provides financial support for only 20% of research-and-development spending, leaving medical institutions to rely on the drug industry to finance the rest of their pharma research needs, creating fears of conflicts of interest.